An Open-Label, Multicenter, Dose-Escalation Phase I Study to Evaluate the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688, A Novel T-cell Bispecific Antibody That Targets the Human Carcinoembryonic Antigen (CEA) on Tumor Cells and CD3 on T Cells, Administered Intravenously in Patients With Locally Advanced and/or Metastatic CEA(+) Solid Tumors

Trial Profile

An Open-Label, Multicenter, Dose-Escalation Phase I Study to Evaluate the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688, A Novel T-cell Bispecific Antibody That Targets the Human Carcinoembryonic Antigen (CEA) on Tumor Cells and CD3 on T Cells, Administered Intravenously in Patients With Locally Advanced and/or Metastatic CEA(+) Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs RO 6958688 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 12 Sep 2017 Preliminary results assessing efficacy and safety of this and one other phase I study (NCT02650713), were presented at the 42nd European Society for Medical Oncology Congress.
    • 06 Jun 2017 Planned number of patients changed from 120 to 185.
    • 06 Jun 2017 Planned End Date changed from 1 Oct 2018 to 27 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top